Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

BACKGROUND: Current clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on the tumor properties, such as programmed cell death ligand 1 expression frequency and tumor mutation burden. Identifying reliable, responsive biomarkers based on...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Hatae, Ryusuke, Chamoto, Kenji, Kim, Young Hak, Sonomura, Kazuhiro, Taneishi, Kei, Kawaguchi, Shuji, Yoshida, Hironori, Ozasa, Hiroaki, Sakamori, Yuichi, Akrami, Maryam, Fagarasan, Sidonia, Masuda, Izuru, Okuno, Yasushi, Matsuda, Fumihiko, Hirai, Toyohiro, Honjo, Tasuku
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098729/
https://ncbi.nlm.nih.gov/pubmed/31855576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.133501
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados